#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | #LCSM Chat @lcsmchat @steele_bob Hey Bob! Thanks for joining. #lcsm |
 | Brendon Stiles @BrendonStilesMD If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm |
| Brendon Stiles @BrendonStilesMD @aepriceny Thanks for joining! #lcsm |
| #LCSM Chat @lcsmchat @JROSE_JNJ @BrendonStilesMD Welcome! #lcsm |
| Brendon Stiles @BrendonStilesMD @steele_bob Hi Bob! #lcsm |
 | Bob Steele @steele_bob RT @BrendonStilesMD: If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm |
 | Henning Willers, MD @HenningWillers I am here to support @BrendonStilesMD and if possible tall about #lungcancer radiotherapy #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Excited for everyone to be here. Don’t know about all of you…but I am exhausted by 2020. #lcsm https://t.co/dGWaTde8By |
| Brendon Stiles @BrendonStilesMD You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
 | Elliot Servais, MD, FACS @ElliotServaisMD Looking forward to the discussion #lcsm |
 | Danielle Pardue @Actorielle RT @BrendonStilesMD: If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm |
| #LCSM Chat @lcsmchat @aepriceny Awesome! #lcsm |
| Brendon Stiles @BrendonStilesMD To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. |
 | Judy Yee @JudyYeeMD RT @grebeccahaines: So proud of @RadiologyACR and this special issue https://t.co/e9SHnlNpiM #healthequity #transgendercare #lcsm #BCAM2020 @zaidirad @EJFloresMD @NinaVincoffMD @JudyYeeMD @DrIanWeissman @ImageScribbler https://t.co/z7Zrk4LwOO |
 | OncLive.com @OncLive Registration is now open! 10/8 6pm MT IPC Lung Cancer chaired by D. Ross Camidge, MD, PhD @CUCancerCenter. Register for a Q&A opportunity with our expert faculty #lcsm #oncliveIPC @OncLiveSOSS https://t.co/E7nIYeiRSA |
 | Sara Whitlock @sjwhitlock Sara here from Ohio #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm |
| Brendon Stiles @BrendonStilesMD @HenningWillers Always appreciate your insight! #lcsm |
 | Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
 | Christine Garcia, MD, MPH @christinemphmd Hi @BrendonStilesMD. Looking forward to the discussion #lcsm! #lcsm |
| Brendon Stiles @BrendonStilesMD @sjwhitlock Ahhh...be still my heart! Missing you. Thanks for joining. DOD not the same without you! #lcsm |
| #LCSM Chat @lcsmchat @HenningWillers @BrendonStilesMD Always happy to “see” you! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm |
| Brendon Stiles @BrendonStilesMD We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
| Brendon Stiles @BrendonStilesMD I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and advocate. #lcsm |
| #LCSM Chat @lcsmchat @ElliotServaisMD Thanks for joining us! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. |
| Brendon Stiles @BrendonStilesMD @christinemphmd Thanks for joining! #lcsm |
| Brendon Stiles @BrendonStilesMD @christinemphmd Thanks for joining! #lcsm |
| #LCSM Chat @lcsmchat @sjwhitlock Hi Sara! #lcsm |
| Brendon Stiles @BrendonStilesMD @ElliotServaisMD Thanks for joining! #lcsm |
| Danielle Pardue @Actorielle Hi, Friends! Danielle in NC here. So happy to be with you all tonight! #lcsm |
| #LCSM Chat @lcsmchat @christinemphmd @BrendonStilesMD Welcome! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
| Brendon Stiles @BrendonStilesMD I would like to disclose conflicts – I am the Board Chair of @lcrf_org & have worked with @astrazeneca @pfizer @bmsnews @genentech. These don’t affect opinions expressed tonight. #lcsm |
 | kristen kimball @KimballKristen Kris Kimball here from Boston, multitasking and trying to keep it together .... #LCSM |
| Elliot Servais, MD, FACS @ElliotServaisMD Elliot Servais, thoracic surgeon, advocate and 2nd ever tweetchat. Happy to be here #lcsm |
| Upstage Lung Cancer @UpstageLungCanc Hi, everyone! Honored as always to be a part! #lcsm |
 | Faces of Lung Cancer @LungCancerFaces Deana in Los Angeles here. Tonight I’ll be tweeting from the @lcsmchat account. #lcsm |
| Brendon Stiles @BrendonStilesMD By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has been an amazing year! #lcsm |
| Brendon Stiles @BrendonStilesMD @LungCancerFaces @lcsmchat The one and only.... #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and advocate. #lcsm |
| Elliot Servais, MD, FACS @ElliotServaisMD Disclosures - Consultant and educator for Intuitive Surgical. My opinions and comments tonight are my own #lcsm |
 | Lung Cancer Sux @LungCancerSux @BrendonStilesMD Hi from CT! Glorianne here. Hubby diagnosed 10 years ago stage 4 nsclc #LCSM |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has been an amazing year! #lcsm |
| Brendon Stiles @BrendonStilesMD In this week’s chat we hope to review some lung cancer highlights from 2020, in particular some of the results shared at #ESMO20 #lcsm |
| #LCSM Chat @lcsmchat @Actorielle Hey you! #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: In this week’s chat we hope to review some lung cancer highlights from 2020, in particular some of the results shared at #ESMO20 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I would like to disclose conflicts – I am the Board Chair of @lcrf_org & have worked with @astrazeneca @pfizer @bmsnews @genentech. These don’t affect opinions expressed tonight. #lcsm |
| Brendon Stiles @BrendonStilesMD Clinicians, researchers, patients and advocates from all over the world attended the #ESMO20 virtually. #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has been an amazing year! #lcsm |
 | Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD Agree! We have seen a record number of @FDAOncology approvals, several of them have immediately changed our clinical practice #LCSM |
| Brendon Stiles @BrendonStilesMD @LungCancerSux Hi. Hope all is well! #lcsm |
| #LCSM Chat @lcsmchat @KimballKristen Hey Kris! Same here. Baby on my lap. Squirmy. #lcsm |
 | Nina @ninadavis Nina from Melbourne Aus here. Sunny day... COVID cases 7 for Victoria. Awesome day 😷 #lcsm |
 | Erika Hlavacek @ErikaHlavacek Erika from Chicago here! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has been an amazing year! #lcsm |
| Brendon Stiles @BrendonStilesMD Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZyKkuA |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: @BrendonStilesMD Agree! We have seen a record number of @FDAOncology approvals, several of them have immediately changed our clinical practice #LCSM |
 | mimiprovenzano @MimiProvenzano #lcsm Hi everybody! |
 | Janet Freeman-Daily @JFreemanDaily Janet here, LC research advocate in Seattle--smoky haze in the upper atmosphere, but air quality is out of the "good" range. #lcsm |
| Lung Cancer Sux @LungCancerSux @BrendonStilesMD Everyone is doing well! Thank goodness! #LCSM |
| Brendon Stiles @BrendonStilesMD Here are the top 5 #lcsm presentations from @APassaroMD https://t.co/yZGKiSN9dj |
| #LCSM Chat @lcsmchat @LungCancerSux @BrendonStilesMD Hey Glorianne! #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZyKkuA |
| Brendon Stiles @BrendonStilesMD @MimiProvenzano Another one of my favorites! Who said 2020 is bad? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: In this week’s chat we hope to review some lung cancer highlights from 2020, in particular some of the results shared at #ESMO20 #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Clinicians, researchers, patients and advocates from all over the world attended the #ESMO20 virtually. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @BrendonStilesMD Agree! We have seen a record number of @FDAOncology approvals, several of them have immediately changed our clinical practice #LCSM |
| Brendon Stiles @BrendonStilesMD We will get started soon. First, a few reminders… #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZyKkuA |
 | Aparna Hegde, MD @notahedge Aparna here from Birmingham #LCSM |
 | Peggy Dennis @peggyddennis #lcsm Peggy joining from Denver. Hi everyone |
| #LCSM Chat @lcsmchat @ninadavis Welcome! #lcsm |
| Brendon Stiles @BrendonStilesMD Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat |
 | Debby Keller, MD @debby_keller RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
| Christine Garcia, MD, MPH @christinemphmd RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZyKkuA |
| Brendon Stiles @BrendonStilesMD If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
| #LCSM Chat @lcsmchat @ErikaHlavacek Hi Erika! #lcsm |
| Brendon Stiles @BrendonStilesMD I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
 | Brandon Meyers @BrandonMeyersMD RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZyKkuA |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: Here are the top 5 #lcsm presentations from @APassaroMD https://t.co/yZGKiSN9dj |
| Janet Freeman-Daily @JFreemanDaily Thanks @BrendonStilesMD for taking on moderating duties for #LCMS Chat this evening -- #ESMO20 summary is a great topic! #lcsm |
 | Shawna Cullen, PhD @slcphd #lcsm Can’t wait to talk about Keynote 5 year OS |
| #LCSM Chat @lcsmchat @MimiProvenzano Hey Mimi! #lcsm |
| Brendon Stiles @BrendonStilesMD We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Here are the top 5 #lcsm presentations from @APassaroMD https://t.co/yZGKiSN9dj |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We will get started soon. First, a few reminders… #lcsm |
| Brendon Stiles @BrendonStilesMD RT @CharuAggarwalMD: @BrendonStilesMD Agree! We have seen a record number of @FDAOncology approvals, several of them have immediately changed our clinical practice #LCSM |
 | Research Bot @ineelbot RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
| Brendon Stiles @BrendonStilesMD T1. What is happening with KRAS? #lcsm |
| #LCSM Chat @lcsmchat @peggyddennis Hi Peggy! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat |
| Brendon Stiles @BrendonStilesMD T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm |
| Brendon Stiles @BrendonStilesMD @DevikaDasMD thanks for being here! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. What is happening with KRAS? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm |
| Aparna Hegde, MD @notahedge Thoracic Onc from Birmingham #lcsm |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm |
| Brendon Stiles @BrendonStilesMD #LCSM |
| mimiprovenzano @MimiProvenzano RT @BrendonStilesMD: By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has been an amazing year! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD T1. Amazing to have a treatment for ANY RAS target. Not that long ago, KRAS was considered undruggable. #lcsm |
| Brendon Stiles @BrendonStilesMD T1. Here were the responses in NSCLC patients. Important to note that many had failed previous therapies. #lcsm https://t.co/1E3khAXM0L |
| Brendon Stiles @BrendonStilesMD @JackWestMD @cityofhope Thanks for joining. Always love your insight. #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD What is NOT happening with KRAS. We have not one, but 2 active drugs, with sotorasib leading the way. It is interesting to see activity in this subset of patients #LCSM |
| Brendon Stiles @BrendonStilesMD T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD T1. Amazing to have a treatment for ANY RAS target. Not that long ago, KRAS was considered undruggable. #lcsm |
 | Jae Kim @DrJaeYKim Jae Kim, thoracic surgeon @cityofhope #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. Here were the responses in NSCLC patients. Important to note that many had failed previous therapies. #lcsm https://t.co/1E3khAXM0L |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Join us in 15 minutes for tonight's #lcsm chat. To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @BrendonStilesMD What is NOT happening with KRAS. We have not one, but 2 active drugs, with sotorasib leading the way. It is interesting to see activity in this subset of patients #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop |
| Danielle Pardue @Actorielle RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD What do our medical oncology friends think? Stand alone or combination therapy is best way forward? #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm |
| Brendon Stiles @BrendonStilesMD RT @CharuAggarwalMD: @BrendonStilesMD What is NOT happening with KRAS. We have not one, but 2 active drugs, with sotorasib leading the way. It is interesting to see activity in this subset of patients #LCSM |
| #LCSM Chat @lcsmchat @DrJaeYKim @cityofhope Welcome! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter. |
| Brendon Stiles @BrendonStilesMD @CharuAggarwalMD T1. Other good drugs are also being developed in the space for other KRAS mutations. #lcsm https://t.co/EzOEY8XaEI |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: What do our medical oncology friends think? Stand alone or combination therapy is best way forward? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @CharuAggarwalMD T1. Other good drugs are also being developed in the space for other KRAS mutations. #lcsm https://t.co/EzOEY8XaEI |
| Henning Willers, MD @HenningWillers @CharuAggarwalMD @BrendonStilesMD Why you think that the ORR has come down from earlier data? #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and advocate. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: @CharuAggarwalMD T1. Other good drugs are also being developed in the space for other KRAS mutations. #lcsm https://t.co/EzOEY8XaEI |
 | 松平秀樹MD🇯🇵𝑯𝒊𝒅𝒆𝒌𝒊 𝑴𝒂𝒕𝒔𝒖𝒅𝒊𝒂𝒓𝒂呼吸器外科医 @matsudaira_h RT @AmCollSurgeons: We are very excited about The Gibbon Lecture! Important findings, critical info. #ACSCC20 #LCSM |
| Bob Steele @steele_bob Will stick to the topic until after LCSM, but wanted to share that I was Dxd by a Neurologist on Monday with COVID-19 caused Dementia #lcsm |
| Brendon Stiles @BrendonStilesMD @JackWestMD T1. Unfortunately, it appears that duration of response is not long – at least in these patients who have failed previous treatments. #lcsm. https://t.co/EDf7XsN33X |
| Janet Freeman-Daily @JFreemanDaily RT @LungCancerFaces: Deana in Los Angeles here. Tonight I’ll be tweeting from the @lcsmchat account. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: In this week’s chat we hope to review some lung cancer highlights from 2020, in particular some of the results shared at #ESMO20 #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Clinicians, researchers, patients and advocates from all over the world attended the #ESMO20 virtually. #lcsm |
 | Andrew Hong @hongdrew RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZyKkuA |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD That is exactly my take, we cannot expect to see the same RRs, and the responses may not be durable, but we finally have a personalized therapy #KRAS #LCSM |
| Brendon Stiles @BrendonStilesMD @christine_lovly Thanks for joining! Always love your input. What will be best combos? #lcsm |
| Henning Willers, MD @HenningWillers @BrendonStilesMD Your #radonc friends think combo is the way forward, and I mean drug combo and not radiation/drug combo #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat |
 | Dr. David Tom Cooke @DavidCookeMD Oh good grief. My thoughts are with you and your family. #LCSM |
| #LCSM Chat @lcsmchat @steele_bob Oh, Bob. That sucks. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @JackWestMD T1. Unfortunately, it appears that duration of response is not long – at least in these patients who have failed previous treatments. #lcsm. https://t.co/EDf7XsN33X |
| Brendon Stiles @BrendonStilesMD @DevikaDasMD T1. Important to note that KRAS-mutated tumors also generally have a good response to immunotherapy. #lcsm https://t.co/ksWuKa5XZN |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: @JackWestMD T1. Unfortunately, it appears that duration of response is not long – at least in these patients who have failed previous treatments. #lcsm. https://t.co/EDf7XsN33X |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: That is exactly my take, we cannot expect to see the same RRs, and the responses may not be durable, but we finally have a personalized therapy #KRAS #LCSM |
| Brendon Stiles @BrendonStilesMD @HenningWillers There has to be a way for radiation to help! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Here are the top 5 #lcsm presentations from @APassaroMD https://t.co/yZGKiSN9dj |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm |
| Bob Steele @steele_bob RT @HenningWillers: @BrendonStilesMD Your #radonc friends think combo is the way forward, and I mean drug combo and not radiation/drug combo #lcsm |
| #LCSM Chat @lcsmchat @christine_lovly @BrendonStilesMD Welcome! Remember to add the #lcsm hashtag so we can all see your tweets. |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. What is happening with KRAS? #lcsm |
| Brendon Stiles @BrendonStilesMD Still...given everything KRAS has been through, amazing to see progress. #lcsm https://t.co/eEweEH0kHB |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD Your #radonc friends think combo is the way forward, and I mean drug combo and not radiation/drug combo #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. Here were the responses in NSCLC patients. Important to note that many had failed previous therapies. #lcsm https://t.co/1E3khAXM0L |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop |
| Danielle Pardue @Actorielle RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD T1. KRAS is no longer the stepchild mutation! @KRASKickers #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: @DevikaDasMD T1. Important to note that KRAS-mutated tumors also generally have a good response to immunotherapy. #lcsm https://t.co/ksWuKa5XZN |
| Henning Willers, MD @HenningWillers A1. How about for KRaS/LKB1 double mutants? They still have lower response rate?! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @DevikaDasMD T1. Important to note that KRAS-mutated tumors also generally have a good response to immunotherapy. #lcsm https://t.co/ksWuKa5XZN |
| Brendon Stiles @BrendonStilesMD RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: What do our medical oncology friends think? Stand alone or combination therapy is best way forward? #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Still...given everything KRAS has been through, amazing to see progress. #lcsm https://t.co/eEweEH0kHB |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T1. KRAS is no longer the stepchild mutation! @KRASKickers #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @CharuAggarwalMD T1. Other good drugs are also being developed in the space for other KRAS mutations. #lcsm https://t.co/EzOEY8XaEI |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD It will be interesting to see how the combination data pans out. We need to also evaluate the role of other biomarkers such as STK11, PTEN and others #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: A1. How about for KRaS/LKB1 double mutants? They still have lower response rate?! #lcsm |
| Brendon Stiles @BrendonStilesMD Moving to T2 soon. #lcsm |
| Brendon Stiles @BrendonStilesMD @harpreet_md Better stated! Sorry! #lcsm |
| Bob Steele @steele_bob RT @HenningWillers: A1. How about for KRaS/LKB1 double mutants? They still have lower response rate?! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Still...given everything KRAS has been through, amazing to see progress. #lcsm https://t.co/eEweEH0kHB |
| Brendon Stiles @BrendonStilesMD T2. Are there any new targets or new drugs that are compelling? #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @BrendonStilesMD It will be interesting to see how the combination data pans out. We need to also evaluate the role of other biomarkers such as STK11, PTEN and others #LCSM |
 | Krishan Jethwa @KrishanJethwa Hi all! Krishan Jethwa, Rad onc at Yale, joining for my first tweet chat. Excited to listen and gather new perspectives #lcsm |
 | Laura Greco @lgreco_ny Laura here from upstate NY joining late. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Lots of new data about drugs being used in different settings. And some new ones. #lcsm |
| Brendon Stiles @BrendonStilesMD @KrishanJethwa Awesome to have you here. #lcsm |
| #LCSM Chat @lcsmchat @harpreet_md @BrendonStilesMD Agree! Remember to add the #lcsm hashtag to your tweets so all can see. Thanks! |
| Janet Freeman-Daily @JFreemanDaily #LCSM -- yes, need tailored approach for KRAS NSCLC subtypes. |
| Brendon Stiles @BrendonStilesMD @lgreco_ny Hi! Hope you are well. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Are there any new targets or new drugs that are compelling? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T1. KRAS is no longer the stepchild mutation! @KRASKickers #lcsm |
| #LCSM Chat @lcsmchat @KrishanJethwa Welcome! #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Definitely new options. Lots of exciting data in the EGFR space with newer drugs and combinations. #lcsm |
| #LCSM Chat @lcsmchat @lgreco_ny Hey lady! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Lots of new data about drugs being used in different settings. And some new ones. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. Moving on to FOURTH generation drugs targeting EGFR. A new drug, BLU-945, showed very encouraging preclinical activity, including for T790M and C797S. #lcsm https://t.co/LU117VLqaK |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Are there any new targets or new drugs that are compelling? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: #LCSM -- yes, need tailored approach for KRAS NSCLC subtypes. |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Lots of new data about drugs being used in different settings. And some new ones. #lcsm |
| Christine Garcia, MD, MPH @christinemphmd @BrendonStilesMD @kRasKickers No longer "the white whale" of mutations #lcsm |
| Laura Greco @lgreco_ny @steele_bob So sorry to read this. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Definitely new options. Lots of exciting data in the EGFR space with newer drugs and combinations. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Moving on to FOURTH generation drugs targeting EGFR. A new drug, BLU-945, showed very encouraging preclinical activity, including for T790M and C797S. #lcsm https://t.co/LU117VLqaK |
| Brendon Stiles @BrendonStilesMD T2. Poster regarding BLU-945 from $BPMC. More evidence that smart drug development is going to continue to make a difference for patients. #lcsm https://t.co/VtMdksacns |
 | Hiroaki Kanemura @hirokane05 RT @TargetedOnc: Atezolizumab demonstrated a significantly longer overall survival in patients with non-small cell lung cancer who had high PD-L1 expression regardless of histologic type compared with platinum-based chemotherapy. https://t.co/jDLY7dOPsJ #lungcancer #lcsm |
| Andrew Hong @hongdrew RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD RT @christinemphmd: @BrendonStilesMD @kRasKickers No longer "the white whale" of mutations #lcsm |
 | Harpreet Singh, MD @harpreet_md @BrendonStilesMD HER2 is interesting. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @harpreet_md: @BrendonStilesMD HER2 is interesting. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T2. Moving on to FOURTH generation drugs targeting EGFR. A new drug, BLU-945, showed very encouraging preclinical activity, including for T790M and C797S. #lcsm https://t.co/LU117VLqaK |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Poster regarding BLU-945 from $BPMC. More evidence that smart drug development is going to continue to make a difference for patients. #lcsm https://t.co/VtMdksacns |
| #LCSM Chat @lcsmchat RT @harpreet_md: @BrendonStilesMD HER2 is interesting. #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T2. Poster regarding BLU-945 from $BPMC. More evidence that smart drug development is going to continue to make a difference for patients. #lcsm https://t.co/VtMdksacns |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T2. Moving on to FOURTH generation drugs targeting EGFR. A new drug, BLU-945, showed very encouraging preclinical activity, including for T790M and C797S. #lcsm https://t.co/LU117VLqaK |
| Brendon Stiles @BrendonStilesMD T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk |
| Bob Steele @steele_bob RT @BrendonStilesMD: T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk |
| Brendon Stiles @BrendonStilesMD T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab and lazertinib showed high response rates in this group. Amivantamab targets both EGFR and MET. #lcsm https://t.co/nqERaBMhzn |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Poster regarding BLU-945 from $BPMC. More evidence that smart drug development is going to continue to make a difference for patients. #lcsm https://t.co/VtMdksacns |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab and lazertinib showed high response rates in this group. Amivantamab targets both EGFR and MET. #lcsm https://t.co/nqERaBMhzn |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab and lazertinib showed high response rates in this group. Amivantamab targets both EGFR and MET. #lcsm https://t.co/nqERaBMhzn |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab and lazertinib showed high response rates in this group. Amivantamab targets both EGFR and MET. #lcsm https://t.co/nqERaBMhzn |
| Brendon Stiles @BrendonStilesMD Here is Chrysalis: #lcsm https://t.co/JAWEoJh57o |
| Hiroaki Kanemura @hirokane05 RT @Latinamd: Important work looking at mechanisms of resistance for newly approved #ret inhibitors for #lungcancer. Via @Annals_Oncology @StephenVLiu @LeciaSequist |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab and lazertinib showed high response rates in this group. Amivantamab targets both EGFR and MET. #lcsm https://t.co/nqERaBMhzn |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Here is Chrysalis: Here is Chrysalis: #lcsm https://t.co/JAWEoJh57o |
 | Christine Lovly, MD, PhD @christine_lovly @BrendonStilesMD I am excited about DDR inhibitors and continued evolution of epigenetic modifiers. Also - ADCs!!!! #LCSM |
| Peggy Dennis @peggyddennis @harpreet_md @lcsmchat @BrendonStilesMD Exciting for sure. Just had second cycle of DS8201a. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Definitely new options. Lots of exciting data in the EGFR space with newer drugs and combinations. #lcsm |
| #LCSM Chat @lcsmchat RT @christine_lovly: @BrendonStilesMD I am excited about DDR inhibitors and continued evolution of epigenetic modifiers. Also - ADCs!!!! #LCSM |
| Brendon Stiles @BrendonStilesMD T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncologists use it as first line therapy? #lcsm https://t.co/n2GkBOBGeD |
| #LCSM Chat @lcsmchat RT @peggyddennis: @harpreet_md @lcsmchat @BrendonStilesMD Exciting for sure. Just had second cycle of DS8201a. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Here is Chrysalis: Here is Chrysalis: #lcsm https://t.co/JAWEoJh57o |
 | Stephen V Liu, MD @StephenVLiu @BrendonStilesMD @LeciaSequist T2: it’s pretty early in the game. We realize that there will be fewer of these triple mutants now that we’re starting with the first line osimertinib but there is another allosteric in development for C797S without T790M which may have more utility. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @christine_lovly: @BrendonStilesMD I am excited about DDR inhibitors and continued evolution of epigenetic modifiers. Also - ADCs!!!! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncologists use it as first line therapy? #lcsm https://t.co/n2GkBOBGeD |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @BrendonStilesMD @LeciaSequist T2: @BrendonStilesMD @LeciaSequist T2: it’s pretty early in the game. We realize that there will be fewer of these triple mutants now that we’re starting with the first line osimertinib but there is another allosteric in development for C797S without T790M which may have more utility. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @peggyddennis: @harpreet_md @lcsmchat @BrendonStilesMD Exciting for sure. Just had second cycle of DS8201a. #lcsm |
| Brendon Stiles @BrendonStilesMD T2. This is more evidence of a relentless drive and ability to make better, next generation drugs. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: Here is Chrysalis: Here is Chrysalis: #lcsm https://t.co/JAWEoJh57o |
| Brendon Stiles @BrendonStilesMD T2. Certainly, we would hope that these drugs come with LESS side effects. Obviously QOL is key. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. This is more evidence of a relentless drive and ability to make better, next generation drugs. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncologists use it as first line therapy? #lcsm https://t.co/n2GkBOBGeD |
| Brendon Stiles @BrendonStilesMD T2. Another #ESMO20 study – EMPOWER trial – suggested that cemiplimab (Libtayo) may be a new option for first line immunotherapy. #lcsm https://t.co/FvLA0oPHD1 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. This is more evidence of a relentless drive and ability to make better, next generation drugs. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Certainly, we would hope that these drugs come with LESS side effects. Obviously QOL is key. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. Another #ESMO20 study – EMPOWER trial – suggested that cemiplimab (Libtayo) may be a new option for first line immunotherapy. #lcsm https://t.co/FvLA0oPHD1 |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncologists use it as first line therapy? #lcsm https://t.co/n2GkBOBGeD |
 | kevin horgan @kevinhorgan RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab and lazertinib showed high response rates in this group. Amivantamab targets both EGFR and MET. #lcsm https://t.co/nqERaBMhzn |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @BrendonStilesMD @LeciaSequist T2: @BrendonStilesMD @LeciaSequist T2: it’s pretty early in the game. We realize that there will be fewer of these triple mutants now that we’re starting with the first line osimertinib but there is another allosteric in development for C797S without T790M which may have more utility. #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T2. Another #ESMO20 study – EMPOWER trial – suggested that cemiplimab (Libtayo) may be a new option for first line immunotherapy. #lcsm https://t.co/FvLA0oPHD1 |
| Brendon Stiles @BrendonStilesMD T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6VtCXlFgwh |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Certainly, we would hope that these drugs come with LESS side effects. Obviously QOL is key. #lcsm |
| Nina @ninadavis Advocate here for LC, not medical but so refreshing to hear that one of the least funded, biggest killers on the planet is moving forward with treatments. Thank you all for what you do. #lcsm |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncologists use it as first line therapy? #lcsm https://t.co/n2GkBOBGeD |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. Another #ESMO20 study – EMPOWER trial – suggested that cemiplimab (Libtayo) may be a new option for first line immunotherapy. #lcsm https://t.co/FvLA0oPHD1 |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD This is another agent, with not surprising activity. I am not sure it fits into our current paradigm #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6VtCXlFgwh |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6VtCXlFgwh |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6VtCXlFgwh |
| #LCSM Chat @lcsmchat RT @ninadavis: Advocate here for LC, not medical but so refreshing to hear that one of the least funded, biggest killers on the planet is moving forward with treatments. Thank you all for what you do. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @BrendonStilesMD This is another agent, with not surprising activity. I am not sure it fits into our current paradigm #LCSM |
| Erika Hlavacek @ErikaHlavacek @BrendonStilesMD Great question. We need studies with alectinib vs. Lorlatinib now. #lcsm |
| Bob Steele @steele_bob RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD T2. Would you use lorlatinib first line? #lcsm |
| Brendon Stiles @BrendonStilesMD T3 coming soon.... #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6VtCXlFgwh |
| #LCSM Chat @lcsmchat RT @ErikaHlavacek: @BrendonStilesMD Great question. We need studies with alectinib vs. Lorlatinib now. #lcsm |
 | CU Cancer Center @CUCancerCenter RT @OncLive: Registration is now open! 10/8 6pm MT IPC Lung Cancer chaired by D. Ross Camidge, MD, PhD @CUCancerCenter. Register for a Q&A opportunity with our expert faculty #lcsm #oncliveIPC @OncLiveSOSS https://t.co/E7nIYeiRSA |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD T2 If we use TKI that targets resistance first, without OS data, are we limiting treatment sequencing options? #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Are these drugs leading to longer survival? To cures? #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Are these drugs leading to longer survival? To cures? #lcsm |
 | Sakti Chakrabarti, MD @doctorC369 RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: @BrendonStilesMD T2 If we use TKI that targets resistance first, without OS data, are we limiting treatment sequencing options? #lcsm |
| Brendon Stiles @BrendonStilesMD T3. At #ESMO20, KEYNOTE-024 showed the potential of long term survival after immunotherapy for PD-L1 positive patients. #lcsm https://t.co/ytB1usmO5i |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @BrendonStilesMD While data from CROWN study is encouraging, it is being compared to crizotinib. Toxicity concerns w/ lorlatinib may limit its adoption in 1L setting #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Are these drugs leading to longer survival? To cures? #lcsm |
 | Manisha🇮🇳🇬🇧🇮🇳 @Doc_Manisha_ RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD T2 If we use TKI that targets resistance first, without OS data, are we limiting treatment sequencing options? #lcsm |
| Brendon Stiles @BrendonStilesMD T3. This was a first line randomized trial of pembrolizumab versus chemotherapy who were PD-L1 positive (EGFR/ALK excluded). #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. At #ESMO20, KEYNOTE-024 showed the potential of long term survival after immunotherapy for PD-L1 positive patients. #lcsm https://t.co/ytB1usmO5i |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @BrendonStilesMD While data from CROWN study is encouraging, it is being compared to crizotinib. Toxicity concerns w/ lorlatinib may limit its adoption in 1L setting #LCSM |
| Henning Willers, MD @HenningWillers @BrendonStilesMD A3. What is the longest survival without recurrence on record for a #EGFR inhibitor? 10 years? @LeciaSequist #LCSM |
| Brendon Stiles @BrendonStilesMD T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. At #ESMO20, KEYNOTE-024 showed the potential of long term survival after immunotherapy for PD-L1 positive patients. #lcsm https://t.co/ytB1usmO5i |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. This was a first line randomized trial of pembrolizumab versus chemotherapy who were PD-L1 positive (EGFR/ALK excluded). #lcsm |
| Brendon Stiles @BrendonStilesMD Anyone know? #lcsm |
| Bob Steele @steele_bob RT @JFreemanDaily: @BrendonStilesMD T2 If we use TKI that targets resistance first, without OS data, are we limiting treatment sequencing options? #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD A3. What is the longest survival without recurrence on record for a #EGFR inhibitor? 10 years? @LeciaSequist #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD The biomarker patient groups have some patients who've been on TKIs for years, but when thinking of TKI "cures" the Gleevec experience gives me pause... #LCSM |
| Stephen V Liu, MD @StephenVLiu @CharuAggarwalMD @BrendonStilesMD T2: I agree. This would’ve been huge 4 years ago. Now, while there’s clearly activity, and the data do look very good, I’m not sure I see a compelling reason to change my practice. I’m certainly willing to accept this as a control arm and I look forward to new combinations. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Anyone know? #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Are the patients alive at 5 years cured? Hard to know but promising. #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @BrendonStilesMD While data from CROWN study is encouraging, it is being compared to crizotinib. Toxicity concerns w/ lorlatinib may limit its adoption in 1L setting #LCSM |
| Christine Garcia, MD, MPH @christinemphmd @BrendonStilesMD #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily RT @StephenVLiu: @CharuAggarwalMD @BrendonStilesMD T2: @CharuAggarwalMD @BrendonStilesMD T2: I agree. This would’ve been huge 4 years ago. Now, while there’s clearly activity, and the data do look very good, I’m not sure I see a compelling reason to change my practice. I’m certainly willing to accept this as a control arm and I look forward to new combinations. #LCSM |
| Brendon Stiles @BrendonStilesMD #lcsm https://t.co/pW4gxCeOdZ |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Are the patients alive at 5 years cured? Hard to know but promising. #lcsm |
| Stephen V Liu, MD @StephenVLiu @JackWestMD @BrendonStilesMD @LeciaSequist T2: it is definitely a smaller slice of the pie than we had originally anticipated. But I can tell you when I do find it, I sure wish there were better options out there... #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD The biomarker patient groups have some patients who've been on TKIs for years, but when thinking of TKI "cures" the Gleevec experience gives me pause... #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @CharuAggarwalMD @BrendonStilesMD T2: @CharuAggarwalMD @BrendonStilesMD T2: I agree. This would’ve been huge 4 years ago. Now, while there’s clearly activity, and the data do look very good, I’m not sure I see a compelling reason to change my practice. I’m certainly willing to accept this as a control arm and I look forward to new combinations. #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Are the patients alive at 5 years cured? Hard to know but promising. #lcsm |
| Henning Willers, MD @HenningWillers @BrendonStilesMD A3. Need to keep up close surveillance. Oligorecurrence after #immunotherapy can happen any time. Even years out. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. This was a first line randomized trial of pembrolizumab versus chemotherapy who were PD-L1 positive (EGFR/ALK excluded). #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. Are the patients alive at 5 years cured? Hard to know but promising. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. Incredible potential exists with combination regimens to extend survival in those patients with PD-L1 <50%. #lcsm |
| Henning Willers, MD @HenningWillers RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM |
| #LCSM Chat @lcsmchat #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: #lcsm https://t.co/pW4gxCeOdZ |
| Christine Garcia, MD, MPH @christinemphmd Definitely one of the highlights for me from #ESMO20 #LCSM @BrendonStilesMD |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @JackWestMD @BrendonStilesMD @LeciaSequist T2: @JackWestMD @BrendonStilesMD @LeciaSequist T2: it is definitely a smaller slice of the pie than we had originally anticipated. But I can tell you when I do find it, I sure wish there were better options out there... #LCSM |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD A3. Need to keep up close surveillance. Oligorecurrence after #immunotherapy can happen any time. Even years out. #lcsm |
| Brendon Stiles @BrendonStilesMD T3. As @tmprowell said: “#lcsm has been transformed by #science. Deep bow to all those who had a hand in this.” https://t.co/PlcmpUgOPL |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Incredible potential exists with combination regimens to extend survival in those patients with PD-L1 <50%. #lcsm |
| #LCSM Chat @lcsmchat RT @christinemphmd: Definitely one of the highlights for me from #ESMO20 #LCSM @BrendonStilesMD |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. As @tmprowell said: T3. As @tmprowell said: “#lcsm has been transformed by #science. Deep bow to all those who had a hand in this.” https://t.co/PlcmpUgOPL |
 | 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐇. 𝐏𝐚𝐫𝐤, 𝐌𝐃 𝐅𝐀𝐂𝐏 @ChandlerHParkMD RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers @BrendonStilesMD @LeciaSequist Don't know for EGFR, but we have ROS1 patients at almost 8 years NED on crizotinib #LCSM |
| Stephen V Liu, MD @StephenVLiu @JackWestMD T2: I spend a lot of time arguing against sequencing strategies. But I agree with Jack: in this instance, it’s hard to ignore. Maybe it’s different because our initial PFS approaches three years with very well tolerated agents. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @HenningWillers: @BrendonStilesMD A3. What is the longest survival without recurrence on record for a #EGFR inhibitor? 10 years? @LeciaSequist #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers @BrendonStilesMD @LeciaSequist Don't know for EGFR, but we have ROS1 patients at almost 8 years NED on crizotinib #LCSM |
| Brendon Stiles @BrendonStilesMD T3. T3. One of my favorite papers from last year describing incredible gains in survival for ALK+ patients. Median OS was 6.8 years at University of Colorado! #lcsm From @LungCancerDr https://t.co/wq7jkLfQKS |
| #LCSM Chat @lcsmchat RT @StephenVLiu: @JackWestMD T2: I spend a lot of time arguing against sequencing strategies. But I agree with Jack: @JackWestMD T2: I spend a lot of time arguing against sequencing strategies. But I agree with Jack: in this instance, it’s hard to ignore. Maybe it’s different because our initial PFS approaches three years with very well tolerated agents. #LCSM |
 | Robert Wiley @robert_wiley RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: #lcsm https://t.co/pW4gxCeOdZ |
| Brendon Stiles @BrendonStilesMD T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding incidence decreases, largely due to targeted therapy. #lcsm https://t.co/AUfocXGLyA |
| Janet Freeman-Daily @JFreemanDaily RT @HenningWillers: @BrendonStilesMD A3. Need to keep up close surveillance. Oligorecurrence after #immunotherapy can happen any time. Even years out. #lcsm |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding incidence decreases, largely due to targeted therapy. #lcsm https://t.co/AUfocXGLyA |
| Henning Willers, MD @HenningWillers RT @BrendonStilesMD: T3. T3. One of my favorite papers from last year describing incredible gains in survival for ALK+ patients. Median OS was 6.8 years at University of Colorado! #lcsm From @LungCancerDr https://t.co/wq7jkLfQKS |
 | Andres F. Cardona @AndresFCardonaZ RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. As @tmprowell said: T3. As @tmprowell said: “#lcsm has been transformed by #science. Deep bow to all those who had a hand in this.” https://t.co/PlcmpUgOPL |
| Shawna Cullen, PhD @slcphd @BrendonStilesMD Does this mean the “target” for survival “cure” may be getting longer then? Say 10 years?? #lcsm |
| Brendon Stiles @BrendonStilesMD RT @HenningWillers: @BrendonStilesMD A3. Need to keep up close surveillance. Oligorecurrence after #immunotherapy can happen any time. Even years out. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. T3. One of my favorite papers from last year describing incredible gains in survival for ALK+ patients. Median OS was 6.8 years at University of Colorado! #lcsm From @LungCancerDr https://t.co/wq7jkLfQKS |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding incidence decreases, largely due to targeted therapy. #lcsm https://t.co/AUfocXGLyA |
| 松平秀樹MD🇯🇵𝑯𝒊𝒅𝒆𝒌𝒊 𝑴𝒂𝒕𝒔𝒖𝒅𝒊𝒂𝒓𝒂呼吸器外科医 @matsudaira_h RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @slcphd: @BrendonStilesMD Does this mean the “target” for survival “cure” may be getting longer then? Say 10 years?? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @slcphd: @BrendonStilesMD Does this mean the “target” for survival “cure” may be getting longer then? Say 10 years?? #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Yes, this was HUGE. BUT, the data hasn't taken the effects of immunotherapy into account, yet. We expect the survival gains to continue to increase over the next several years! #LCSM |
| Danielle Pardue @Actorielle @HenningWillers @BrendonStilesMD I hold my breath every time I see this discussed bc my mom just passed 5.5 years since dx and her only tx so far was 2 years on Avelumab. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Yes, this was HUGE. BUT, the data hasn't taken the effects of immunotherapy into account, yet. We expect the survival gains to continue to increase over the next several years! #LCSM |
| Danielle Pardue @Actorielle RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM |
| #LCSM Chat @lcsmchat RT @Actorielle: @HenningWillers @BrendonStilesMD I hold my breath every time I see this discussed bc my mom just passed 5.5 years since dx and her only tx so far was 2 years on Avelumab. #lcsm |
 | Lecia Sequist, MD, MPH @LeciaSequist @HenningWillers @BrendonStilesMD I have a patient who started gefitinib in 2002 and has not relapsed yet. 💕 @EGFRResisters #LCSM |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| 松平秀樹MD🇯🇵𝑯𝒊𝒅𝒆𝒌𝒊 𝑴𝒂𝒕𝒔𝒖𝒅𝒊𝒂𝒓𝒂呼吸器外科医 @matsudaira_h RT @BrendonStilesMD: What do our medical oncology friends think? Stand alone or combination therapy is best way forward? #lcsm |
| Brendon Stiles @BrendonStilesMD @CharuAggarwalMD Yes..amazing to consider this was pre-immunotherapy and pre-next gen targeted therapy. Only going to get better. #lcsm |
| Henning Willers, MD @HenningWillers RT @LeciaSequist: @HenningWillers @BrendonStilesMD I have a patient who started gefitinib in 2002 and has not relapsed yet. 💕 @EGFRResisters #LCSM |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. As @tmprowell said: T3. As @tmprowell said: “#lcsm has been transformed by #science. Deep bow to all those who had a hand in this.” https://t.co/PlcmpUgOPL |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @CharuAggarwalMD Yes..amazing to consider this was pre-immunotherapy and pre-next gen targeted therapy. Only going to get better. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. T3. One of my favorite papers from last year describing incredible gains in survival for ALK+ patients. Median OS was 6.8 years at University of Colorado! #lcsm From @LungCancerDr https://t.co/wq7jkLfQKS |
| Brendon Stiles @BrendonStilesMD @LeciaSequist @HenningWillers @EGFRResisters Amazing! #lcsm |
| 松平秀樹MD🇯🇵𝑯𝒊𝒅𝒆𝒌𝒊 𝑴𝒂𝒕𝒔𝒖𝒅𝒊𝒂𝒓𝒂呼吸器外科医 @matsudaira_h RT @CharuAggarwalMD: @BrendonStilesMD What is NOT happening with KRAS. We have not one, but 2 active drugs, with sotorasib leading the way. It is interesting to see activity in this subset of patients #LCSM |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding incidence decreases, largely due to targeted therapy. #lcsm https://t.co/AUfocXGLyA |
| Brendon Stiles @BrendonStilesMD RT @JackWestMD: |
 | Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD T3 Also looking to look at some real world follow up data with patients with co-morbidities and see if this OS data translates ? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @JackWestMD: |
| Henning Willers, MD @HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters A3. That has to be a true cure! Is the patient still on the drug? Would you ever stop? #LCSM |
| Brendon Stiles @BrendonStilesMD T4 coming....earlier stage lung cancer. Finally something I know about. #lcsm |
| Bob Steele @steele_bob RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding incidence decreases, largely due to targeted therapy. #lcsm https://t.co/AUfocXGLyA |
| #LCSM Chat @lcsmchat RT @LeciaSequist: @HenningWillers @BrendonStilesMD I have a patient who started gefitinib in 2002 and has not relapsed yet. 💕 @EGFRResisters #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: @CharuAggarwalMD Yes..amazing to consider this was pre-immunotherapy and pre-next gen targeted therapy. Only going to get better. #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD T4. What is happening in earlier stage lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @LeciaSequist @BrendonStilesMD @EGFRResisters A3. That has to be a true cure! Is the patient still on the drug? Would you ever stop? #LCSM |
| Janet Freeman-Daily @JFreemanDaily @HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters Can you call it a "cure" if you have to keep taking the drug forever to keep the cancer controlled? Or is it "chronic illness"? #LCSM |
 | Matthew Steliga MD FACS @SteligaMD @BrendonStilesMD @NEJM Thank me for sharing- I will have to read for details. I wonder if early detection played some role in decreasing mortality as well. #LCSM. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. What is happening in earlier stage lung cancer? #lcsm |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: @HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters Can you call it a "cure" if you have to keep taking the drug forever to keep the cancer controlled? Or is it "chronic illness"? #LCSM |
| Christine Lovly, MD, PhD @christine_lovly @BrendonStilesMD @NEJM True - for NSCLC. But not for SCLC. We need a lot more studies to understand lineage plasticity, tumor heterogeneity, + new treatment paradigms for SCLC. Overall survival of 12mo with “modern” chemotherapy plus immunotherapy is clearly not enough. #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T3. At #ESMO20, KEYNOTE-024 showed the potential of long term survival after immunotherapy for PD-L1 positive patients. #lcsm https://t.co/ytB1usmO5i |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. What is happening in earlier stage lung cancer? #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters Can you call it a "cure" if you have to keep taking the drug forever to keep the cancer controlled? Or is it "chronic illness"? #LCSM |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz |
| #LCSM Chat @lcsmchat RT @christine_lovly: @BrendonStilesMD @NEJM True - for NSCLC. But not for SCLC. We need a lot more studies to understand lineage plasticity, tumor heterogeneity, + new treatment paradigms for SCLC. Overall survival of 12mo with “modern” chemotherapy plus immunotherapy is clearly not enough. #LCSM |
| Brendon Stiles @BrendonStilesMD T4. More data presented regarding adjuvant osimertinib after surgery for EGFR+ patients (ADAURA). Remarkable decrease in recurrences in the brain. #lcsm https://t.co/IKBCTUJPMZ |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. More data presented regarding adjuvant osimertinib after surgery for EGFR+ patients (ADAURA). Remarkable decrease in recurrences in the brain. #lcsm https://t.co/IKBCTUJPMZ |
| Brendon Stiles @BrendonStilesMD T4. Results were published in the @nejm #lcsm https://t.co/iv9yxhIQRg |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T3. Incredible potential exists with combination regimens to extend survival in those patients with PD-L1 <50%. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Results were published in the @nejm #lcsm https://t.co/iv9yxhIQRg |
| Brendon Stiles @BrendonStilesMD T4. You can see the results presented here by Dr. Tsuboi. #lcsm https://t.co/V7c2GpkHCr |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding incidence decreases, largely due to targeted therapy. #lcsm https://t.co/AUfocXGLyA |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding incidence decreases, largely due to targeted therapy. #lcsm https://t.co/AUfocXGLyA |
| Shawna Cullen, PhD @slcphd @BrendonStilesMD Very interested in sequencing here (early stage). What regimens in what order are showing greater effect than SOC? #lcsm |
| Stephen V Liu, MD @StephenVLiu @JackWestMD T2: KRAS is more common. Huge impact. Very impressive safety profile (critical). My enthusiasm for the ultra high “disease control rate” was tempered when they reported a fairly short median duration of stable disease. But undeniably, an important step. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. More data presented regarding adjuvant osimertinib after surgery for EGFR+ patients (ADAURA). Remarkable decrease in recurrences in the brain. #lcsm https://t.co/IKBCTUJPMZ |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. Results were published in the @nejm #lcsm https://t.co/iv9yxhIQRg |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T4. More data presented regarding adjuvant osimertinib after surgery for EGFR+ patients (ADAURA). Remarkable decrease in recurrences in the brain. #lcsm https://t.co/IKBCTUJPMZ |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. You can see the results presented here by Dr. Tsuboi. #lcsm https://t.co/V7c2GpkHCr |
| Brendon Stiles @BrendonStilesMD T4. Adjuvant Osimertinb markedly decreased recurrences. Is this important to cancer patients or just OS? #lcsm https://t.co/fwi6S56LW2 |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T4. What is happening in earlier stage lung cancer? #lcsm |
| Christine Garcia, MD, MPH @christinemphmd Encouraging to see therapy options for patients with #lungcancer improving each year! #lcsm @lcsmchat |
| Brendon Stiles @BrendonStilesMD Great point. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: https://t.co/rQvh77I8fv |
 | Maaz Afghan @maazafghan RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @StephenVLiu @JackWestMD That is the point right, this is a small step. We cannot let it be tempered by the "low" RR. We all know that this is not going to be an easy win. Step in the right direction. Small step #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @slcphd: @BrendonStilesMD Very interested in sequencing here (early stage). What regimens in what order are showing greater effect than SOC? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. Adjuvant Osimertinb markedly decreased recurrences. Is this important to cancer patients or just OS? #lcsm https://t.co/fwi6S56LW2 |
 | Ozyman Diaz @tristramshanty1 RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM |
 | Andrea Borondy Kitts @findlungcancer So well deserved - Congratulations! @CriswellAngela Angela Criswell Wins the the 2020 Timothy W. Mullett, MD, Lung Cancer Prevention Award https://t.co/zuWuCpEOzr #lcsm @DrewMoghanaki @BrendonStilesMD @sands_jacob @SandlerRhodes |
| Janet Freeman-Daily @JFreemanDaily RT @christinemphmd: Encouraging to see therapy options for patients with #lungcancer improving each year! #lcsm @lcsmchat |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: https://t.co/rQvh77I8fv |
| Brendon Stiles @BrendonStilesMD T4. In my opinion, continuing to move biomarker driven therapy into neoadjuvant and/or adjuvant treatment for earlier stage patients is the path forward. #lcsm |
| Henning Willers, MD @HenningWillers @BrendonStilesMD T4. For localized disease only cure is important, min 5 year survival without recurrence #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. You can see the results presented here by Dr. Tsuboi. #lcsm https://t.co/V7c2GpkHCr |
| #LCSM Chat @lcsmchat RT @slcphd: @BrendonStilesMD Very interested in sequencing here (early stage). What regimens in what order are showing greater effect than SOC? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Adjuvant Osimertinb markedly decreased recurrences. Is this important to cancer patients or just OS? #lcsm https://t.co/fwi6S56LW2 |
| #LCSM Chat @lcsmchat RT @christinemphmd: Encouraging to see therapy options for patients with #lungcancer improving each year! #lcsm @lcsmchat |
| Matthew Steliga MD FACS @SteligaMD @BrendonStilesMD @NEJM Thank you for sharing- I will have to read for details. I wonder if early detection played some role in decreasing mortality as well. #LCSM. |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD T4. Another important study was the LungART trial which evaluated post operative radiation (PORT) in patients with resected N2 disease. Good summary by @jsoriamd #lcsm https://t.co/xf99hkzepu |
| Janet Freeman-Daily @JFreemanDaily RT @HenningWillers: @BrendonStilesMD T4. For localized disease only cure is important, min 5 year survival without recurrence #lcsm |
 | Santhosh Ambika @RenoHemonc @StephenVLiu @JackWestMD controlling MAP3k/PI3K SHP-2 pathway very important for durable response with Soto.#LCSM |
| Devika Das, MD, MSHQS @DevikaDasMD @BrendonStilesMD A4 ADAURA- will be the best case for shared decision making in the adjuvant setting. PORT - puts to rest what we kind of knew so yes practice changing. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: https://t.co/rQvh77I8fv |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: @StephenVLiu @JackWestMD That is the point right, this is a small step. We cannot let it be tempered by the "low" RR. We all know that this is not going to be an easy win. Step in the right direction. Small step #LCSM |
| Brendon Stiles @BrendonStilesMD T4. LungART failed to show improvement in DFS with addition of adjuvant radiation, although it did decrease mediastinal relapse. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. In my opinion, continuing to move biomarker driven therapy into neoadjuvant and/or adjuvant treatment for earlier stage patients is the path forward. #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD T4. For localized disease only cure is important, min 5 year survival without recurrence #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Another important study was the LungART trial which evaluated post operative radiation (PORT) in patients with resected N2 disease. Good summary by @jsoriamd #lcsm https://t.co/xf99hkzepu |
| #LCSM Chat @lcsmchat RT @RenoHemonc: @StephenVLiu @JackWestMD controlling MAP3k/PI3K SHP-2 pathway very important for durable response with Soto.#LCSM |
| #LCSM Chat @lcsmchat RT @DevikaDasMD: @BrendonStilesMD A4 ADAURA- will be the best case for shared decision making in the adjuvant setting. PORT - puts to rest what we kind of knew so yes practice changing. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. LungART study showed a tradeoff – decreased progression/recurrence with radiation came at expense of toxicity and a slight increase in 2nd cancers. #lcsm https://t.co/LpEgZGMyt0 |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. LungART study showed a tradeoff – decreased progression/recurrence with radiation came at expense of toxicity and a slight increase in 2nd cancers. #lcsm https://t.co/LpEgZGMyt0 |
| Brendon Stiles @BrendonStilesMD RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily RT @RenoHemonc: @StephenVLiu @JackWestMD controlling MAP3k/PI3K SHP-2 pathway very important for durable response with Soto.#LCSM |
| Brendon Stiles @BrendonStilesMD T4. Although we can’t recommend adjuvant PORT as standard of care, both arms showed great DFS for stage III disease. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. LungART failed to show improvement in DFS with addition of adjuvant radiation, although it did decrease mediastinal relapse. #lcsm |
 | Jen Buhay, PhD 💙 @JenBuhayPhD RT @CharuAggarwalMD: That is exactly my take, we cannot expect to see the same RRs, and the responses may not be durable, but we finally have a personalized therapy #KRAS #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Although we can’t recommend adjuvant PORT as standard of care, both arms showed great DFS for stage III disease. #lcsm |
| Henning Willers, MD @HenningWillers @JackWestMD A4. We will have to review paper. Difficult trial with large fields and unexpected toxicity that could have negated any survival benefit from reducing local recurrence. Just like PORT meta-analysis [sigh] #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @JackWestMD A4. We will have to review paper. Difficult trial with large fields and unexpected toxicity that could have negated any survival benefit from reducing local recurrence. Just like PORT meta-analysis [sigh] #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Also more great w.ork on neoadjuvant immunotherapy for lung cancer. PRINCEPS trial showed 14% MPR with just a single dose of atezolizumab. #lcsm https://t.co/DCepMx3Ofe |
| Brendon Stiles @BrendonStilesMD T4. Such study designs allow for great translational research that will help us better select patients for neoadjuvant immunotherapy. @bmassutis #lcsm https://t.co/S7kEfuUVAb |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Also more great w.ork on neoadjuvant immunotherapy for lung cancer. PRINCEPS trial showed 14% MPR with just a single dose of atezolizumab. #lcsm https://t.co/DCepMx3Ofe |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Such study designs allow for great translational research that will help us better select patients for neoadjuvant immunotherapy. @bmassutis #lcsm https://t.co/S7kEfuUVAb |
| Henning Willers, MD @HenningWillers @BrendonStilesMD A4. The increase in 2nd cancers difficult to understand. No other data to suggest that lung radiation increases risk of lung cancer to my knowledge. Generally radiation induced cancer also have latency > 5 years. #lcsm |
| Brendon Stiles @BrendonStilesMD T4. Results were also presented from the IoNESCO trial with neoadjuvant durvalumab with robust 18.6% MPR. #lcsm |
| Brendon Stiles @BrendonStilesMD @HenningWillers Agree. #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD A4. The increase in 2nd cancers difficult to understand. No other data to suggest that lung radiation increases risk of lung cancer to my knowledge. Generally radiation induced cancer also have latency > 5 years. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T4. Results were also presented from the IoNESCO trial with neoadjuvant durvalumab with robust 18.6% MPR. #lcsm |
| Elliot Servais, MD, FACS @ElliotServaisMD @HenningWillers @JackWestMD #LCSM Agreed, need to see manuscript, but this will be practice changing I suspect. |
| Janet Freeman-Daily @JFreemanDaily RT @HenningWillers: @JackWestMD A4. We will have to review paper. Difficult trial with large fields and unexpected toxicity that could have negated any survival benefit from reducing local recurrence. Just like PORT meta-analysis [sigh] #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. Also more great w.ork on neoadjuvant immunotherapy for lung cancer. PRINCEPS trial showed 14% MPR with just a single dose of atezolizumab. #lcsm https://t.co/DCepMx3Ofe |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. Such study designs allow for great translational research that will help us better select patients for neoadjuvant immunotherapy. @bmassutis #lcsm https://t.co/S7kEfuUVAb |
| Janet Freeman-Daily @JFreemanDaily RT @HenningWillers: @BrendonStilesMD A4. The increase in 2nd cancers difficult to understand. No other data to suggest that lung radiation increases risk of lung cancer to my knowledge. Generally radiation induced cancer also have latency > 5 years. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T4. Results were also presented from the IoNESCO trial with neoadjuvant durvalumab with robust 18.6% MPR. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @ElliotServaisMD: @HenningWillers @JackWestMD #LCSM Agreed, need to see manuscript, but this will be practice changing I suspect. |
| Henning Willers, MD @HenningWillers @BrendonStilesMD A4. Will need subset analysis to possibly identify patients with unfavorable tumors (multiple nodes, ECE), upper lobe location who might still benefit from #radiotherapy. Modern IMRT/VMAT can be used with little toxicity #lcsm |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Brendon Stiles @BrendonStilesMD @HenningWillers New phenomenon. Anti-abscopal effect? #lcsm |
| Brendon Stiles @BrendonStilesMD RT @HenningWillers: @BrendonStilesMD A4. Will need subset analysis to possibly identify patients with unfavorable tumors (multiple nodes, ECE), upper lobe location who might still benefit from #radiotherapy. Modern IMRT/VMAT can be used with little toxicity #lcsm |
| #LCSM Chat @lcsmchat RT @HenningWillers: @BrendonStilesMD A4. Will need subset analysis to possibly identify patients with unfavorable tumors (multiple nodes, ECE), upper lobe location who might still benefit from #radiotherapy. Modern IMRT/VMAT can be used with little toxicity #lcsm |
| Brendon Stiles @BrendonStilesMD T5 on way.... #lcsm |
| Henning Willers, MD @HenningWillers @JackWestMD sadly you may be right (ok I am somewhat biased) #lcsm |
| Brendon Stiles @BrendonStilesMD T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #lcsm |
 | Laronica Conway @louisianagirl91 RT @JFreemanDaily: @HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters Can you call it a "cure" if you have to keep taking the drug forever to keep the cancer controlled? Or is it "chronic illness"? #LCSM |
| Brendon Stiles @BrendonStilesMD T5. I think they are steadily getting better. Many are free to patients and advocates, but could better engage. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: @HenningWillers New phenomenon. Anti-abscopal effect? #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #lcsm |
| Laronica Conway @louisianagirl91 RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. I think they are steadily getting better. Many are free to patients and advocates, but could better engage. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. I think they are steadily getting better. Many are free to patients and advocates, but could better engage. #LCSM |
| Lung Cancer Sux @LungCancerSux RT @BrendonStilesMD: T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #lcsm |
| Laronica Conway @louisianagirl91 RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6VtCXlFgwh |
| Brendon Stiles @BrendonStilesMD T5. I thought #ESMO20 did a great job. So did @tmprowell #lcsm https://t.co/Rl7f0Iiie4 |
| Matthew Steliga MD FACS @SteligaMD @BrendonStilesMD T4. It would also be really interesting to use biomarker driven therapy in the immediate preop / perioperative time period. We know circulating tumor cells can ⬆️ with surgery. #LCSM. |
| Matthew Steliga MD FACS @SteligaMD RT @BrendonStilesMD: T4. In my opinion, continuing to move biomarker driven therapy into neoadjuvant and/or adjuvant treatment for earlier stage patients is the path forward. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #lcsm |
| Laronica Conway @louisianagirl91 RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD The virtual conferences do give advocates more access to presentations, yet less interaction with experts. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Certainly not having to travel is nice and may ultimately allow for more collaborative efforts. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. I thought #ESMO20 did a great job. So did @tmprowell #lcsm https://t.co/Rl7f0Iiie4 |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Certainly not having to travel is nice and may ultimately allow for more collaborative efforts. #lcsm |
| Brendon Stiles @BrendonStilesMD RT @JFreemanDaily: The virtual conferences do give advocates more access to presentations, yet less interaction with experts. #lcsm |
 | virginia litle @vlitlemd RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. I thought #ESMO20 did a great job. So did @tmprowell #lcsm https://t.co/Rl7f0Iiie4 |
| #LCSM Chat @lcsmchat RT @SteligaMD: @BrendonStilesMD T4. It would also be really interesting to use biomarker driven therapy in the immediate preop / perioperative time period. We know circulating tumor cells can ⬆️ with surgery. #LCSM. |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD The virtual conferences do give advocates more access to presentations, yet less interaction with experts. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Ability to review sessions “on demand” allows people to not have to race from session to session. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Certainly not having to travel is nice and may ultimately allow for more collaborative efforts. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. There is a sense of screen fatigue however…. #lcsm https://t.co/b8admpGlwo |
| Laronica Conway @louisianagirl91 @BrendonStilesMD Gaaaaahh can’t believe I forgot about the chat!!! This is good stuff!! I’ll have to catch up on all this good info later!! #lcsm |
| Brendon Stiles @BrendonStilesMD T5. And I certainly miss the informal conversations that happen between sessions. Networking opportunities are lost. #lcsm |
| Brendon Stiles @BrendonStilesMD @louisianagirl91 Always forgiven! #lcsm |
| virginia litle @vlitlemd Progress sorely needed #Lcsm For our patients. Good news indeed |
| mimiprovenzano @MimiProvenzano @BrendonStilesMD Silver linings! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Ability to review sessions “on demand” allows people to not have to race from session to session. #lcsm |
 | Pashtoon Kasi MD, MS @pashtoonkasi RT @PestanaRC: Very nice article by @pashtoonkasi on ctDNA kinetics and response to immunotherapy! |
| Brendon Stiles @BrendonStilesMD @DevikaDasMD Great, great points! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. There is a sense of screen fatigue however…. #lcsm https://t.co/b8admpGlwo |
| Elliot Servais, MD, FACS @ElliotServaisMD @BrendonStilesMD T5/ #LCSM I would love to see the experience with virtual conferences extend to post-pandemic times with a hybrid approach. In-person conferences with option to remote in. Would maximize impact and reach of conferences. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. And I certainly miss the informal conversations that happen between sessions. Networking opportunities are lost. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @BrendonStilesMD T5. True, but virtual meetings also encourage more in-seat time, with fewer breaks. Also, most people now have to parallel process conferences with bandwidth demands from work (and sometimes family). #LCSM |
| #LCSM Chat @lcsmchat @BrendonStilesMD And the photo ops! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Ability to review sessions “on demand” allows people to not have to race from session to session. #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8 |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. There is a sense of screen fatigue however…. #lcsm https://t.co/b8admpGlwo |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. And I certainly miss the informal conversations that happen between sessions. Networking opportunities are lost. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8 |
| #LCSM Chat @lcsmchat RT @ElliotServaisMD: @BrendonStilesMD T5/ #LCSM I would love to see the experience with virtual conferences extend to post-pandemic times with a hybrid approach. In-person conferences with option to remote in. Would maximize impact and reach of conferences. |
| Brendon Stiles @BrendonStilesMD RT @ElliotServaisMD: @BrendonStilesMD T5/ #LCSM I would love to see the experience with virtual conferences extend to post-pandemic times with a hybrid approach. In-person conferences with option to remote in. Would maximize impact and reach of conferences. |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @BrendonStilesMD T5. True, but virtual meetings also encourage more in-seat time, with fewer breaks. Also, most people now have to parallel process conferences with bandwidth demands from work (and sometimes family). #LCSM |
| Stephen V Liu, MD @StephenVLiu RT @BrendonStilesMD: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: https://t.co/rQvh77I8fv |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8 |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8 |
| Janet Freeman-Daily @JFreemanDaily RT @ElliotServaisMD: @BrendonStilesMD T5/ #LCSM I would love to see the experience with virtual conferences extend to post-pandemic times with a hybrid approach. In-person conferences with option to remote in. Would maximize impact and reach of conferences. |
| Janet Freeman-Daily @JFreemanDaily RT @lcsmchat: @BrendonStilesMD And the photo ops! #lcsm |
| Brendon Stiles @BrendonStilesMD T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17. |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8 |
| Brendon Stiles @BrendonStilesMD Almost time to wind the chat down. This has been an incredible discussion. #lcsm |
| Elliot Servais, MD, FACS @ElliotServaisMD RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17. |
| Brendon Stiles @BrendonStilesMD Great video recap of #ESMO20 #LungCancer #lcsm from @peters_solange @DrSanjayPopat @APassaroMD and Dr. Cappuzzo. https://t.co/fSX4H8ozpK |
| Laronica Conway @louisianagirl91 @BrendonStilesMD T5: I “watched” the FREE virtual @AACR patient advocate webinar today. I loved being able to work while still listening and bookmarking links to pertinent info. Free to all was very beneficial. I also liked seeing others questions in the chat box. #lcsm |
| Danielle Pardue @Actorielle RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17. |
| Brendon Stiles @BrendonStilesMD Please share your closing thoughts! #lcsm |
 | Elizabeth McKenna @ElizSMcKenna RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: Great video recap of #ESMO20 #LungCancer #lcsm from @peters_solange @DrSanjayPopat @APassaroMD and Dr. Cappuzzo. https://t.co/fSX4H8ozpK |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Great video recap of #ESMO20 #LungCancer #lcsm from @peters_solange @DrSanjayPopat @APassaroMD and Dr. Cappuzzo. https://t.co/fSX4H8ozpK |
| Upstage Lung Cancer @UpstageLungCanc RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17. |
| Brendon Stiles @BrendonStilesMD Thanks to all of the #lcsm community who joined. And BIG thanks to #ESMO20 for highlighting #LungCancer |
| #LCSM Chat @lcsmchat RT @louisianagirl91: @BrendonStilesMD T5: @BrendonStilesMD T5: I “watched” the FREE virtual @AACR patient advocate webinar today. I loved being able to work while still listening and bookmarking links to pertinent info. Free to all was very beneficial. I also liked seeing others questions in the chat box. #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Please share your closing thoughts! #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to #ESMO20 for highlighting #LungCancer |
| Janet Freeman-Daily @JFreemanDaily @lcsmchat @BrendonStilesMD And the competitions for longest ribbon train ... #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17. |
| Christine Garcia, MD, MPH @christinemphmd @BrendonStilesMD Def miss the networking opportunities, social events, and stepping out of your own clinic space to find ways to improve. More affordable as it's tough to travel - both time, $, finding coverage. However #LCSM has def helped! |
| Danielle Pardue @Actorielle RT @louisianagirl91: @BrendonStilesMD T5: @BrendonStilesMD T5: I “watched” the FREE virtual @AACR patient advocate webinar today. I loved being able to work while still listening and bookmarking links to pertinent info. Free to all was very beneficial. I also liked seeing others questions in the chat box. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Almost time to wind the chat down. This has been an incredible discussion. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Great video recap of #ESMO20 #LungCancer #lcsm from @peters_solange @DrSanjayPopat @APassaroMD and Dr. Cappuzzo. https://t.co/fSX4H8ozpK |
 | Christian Rolfo @ChristianRolfo Great #LCSM discussion with @BrendonStilesMD with very important questions! Thanks Brendon! Great participation as always from @StephenVLiu @n8pennell and @CharuAggarwalMD @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @louisianagirl91: @BrendonStilesMD T5: @BrendonStilesMD T5: I “watched” the FREE virtual @AACR patient advocate webinar today. I loved being able to work while still listening and bookmarking links to pertinent info. Free to all was very beneficial. I also liked seeing others questions in the chat box. #lcsm |
| Elliot Servais, MD, FACS @ElliotServaisMD @BrendonStilesMD #LCSM This is a great forum. Congrats to #LCSM and the moderator @BrendonStilesMD. |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Please share your closing thoughts! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to #ESMO20 for highlighting #LungCancer |
| Brendon Stiles @BrendonStilesMD RT @christinemphmd: @BrendonStilesMD Def miss the networking opportunities, social events, and stepping out of your own clinic space to find ways to improve. More affordable as it's tough to travel - both time, $, finding coverage. However #LCSM has def helped! |
| Janet Freeman-Daily @JFreemanDaily RT @christinemphmd: @BrendonStilesMD Def miss the networking opportunities, social events, and stepping out of your own clinic space to find ways to improve. More affordable as it's tough to travel - both time, $, finding coverage. However #LCSM has def helped! |
| Danielle Pardue @Actorielle Thank you for everything, @BrendonStilesMD and @lcsmchat! #lcsm |
| #LCSM Chat @lcsmchat Thanks for moderating tonight’s #LCSM chat @BrendonStilesMD. We appreciate you! |
| #LCSM Chat @lcsmchat RT @christinemphmd: @BrendonStilesMD Def miss the networking opportunities, social events, and stepping out of your own clinic space to find ways to improve. More affordable as it's tough to travel - both time, $, finding coverage. However #LCSM has def helped! |
| #LCSM Chat @lcsmchat RT @ChristianRolfo: Great #LCSM discussion with @BrendonStilesMD with very important questions! Thanks Brendon! Great participation as always from @StephenVLiu @n8pennell and @CharuAggarwalMD @lcsmchat |
| #LCSM Chat @lcsmchat RT @ElliotServaisMD: @BrendonStilesMD #LCSM This is a great forum. Congrats to #LCSM and the moderator @BrendonStilesMD. |
| #LCSM Chat @lcsmchat RT @JackWestMD: |
| Christian Rolfo @ChristianRolfo And @ialsc liquid biopsy tomorrow@and Saturday! https://t.co/PJu8nL0RnZ https://t.co/o1a7EsUZ2H |
| Janet Freeman-Daily @JFreemanDaily Thanks to moderator @BrendonStilesMD for preparing a great set of tweets for tonight's #LCSM Chat on #lungcancer at #ESMO20! |
| 松平秀樹MD🇯🇵𝑯𝒊𝒅𝒆𝒌𝒊 𝑴𝒂𝒕𝒔𝒖𝒅𝒊𝒂𝒓𝒂呼吸器外科医 @matsudaira_h RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17. |
| Brendon Stiles @BrendonStilesMD We really appreciate everyone for joining the #lcsm community tonight. Always good to catch up and hear everyone's thoughts. Thanks for taking time from your busy schedules. Miss you all! |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Thanks to moderator @BrendonStilesMD for preparing a great set of tweets for tonight's #LCSM Chat on #lungcancer at #ESMO20! |
| Janet Freeman-Daily @JFreemanDaily RT @ElliotServaisMD: @BrendonStilesMD #LCSM This is a great forum. Congrats to #LCSM and the moderator @BrendonStilesMD. |
| Laronica Conway @louisianagirl91 RT @Actorielle: Thank you for everything, @BrendonStilesMD and @lcsmchat! #lcsm |
 | Deb Smith 🌻🟧 @debsmithbeach @louisianagirl91 @BrendonStilesMD #LCSM Me too....sorry. I’ll look at transcript tomorrow. |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: We really appreciate everyone for joining the #lcsm community tonight. Always good to catch up and hear everyone's thoughts. Thanks for taking time from your busy schedules. Miss you all! |
| Christine Garcia, MD, MPH @christinemphmd @BrendonStilesMD T5. Not running from the far ends of a conference center then getting caught in the crowds also helps! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @JackWestMD: |
| Janet Freeman-Daily @JFreemanDaily RT @BrendonStilesMD: We really appreciate everyone for joining the #lcsm community tonight. Always good to catch up and hear everyone's thoughts. Thanks for taking time from your busy schedules. Miss you all! |
| Brendon Stiles @BrendonStilesMD Still room for this - sure to be a great conference. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @christinemphmd: @BrendonStilesMD T5. Not running from the far ends of a conference center then getting caught in the crowds also helps! #LCSM |
| Henning Willers, MD @HenningWillers @BrendonStilesMD Thank you for making it multidisciplinary :-) #lcsm |
| #LCSM Chat @lcsmchat RT @BrendonStilesMD: Still room for this - sure to be a great conference. #lcsm |
| Christine Garcia, MD, MPH @christinemphmd @lcsmchat @BrendonStilesMD Thanks! Great moderating @BrendonStilesMD! #LCSM @LSCM |
| Stephen V Liu, MD @StephenVLiu RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17. |
 | ann price @aepriceny @BrendonStilesMD #lcsm Thanks for all you do Dr.Stiles. Cancer free, now, but all the ideas you guy knock around every month could prolong my life for another 5 if old age doesn’t get me first. Xxx. |
| Lung Cancer Sux @LungCancerSux RT @JackWestMD: |
| Sara Whitlock @sjwhitlock @BrendonStilesMD @lcsmchat Great job as always. Thanks for all you do. #lcsm |
| Harpreet Singh, MD @harpreet_md @BrendonStilesMD Wonderful chat! #LCSM |
| Janet Freeman-Daily @JFreemanDaily Check out the @IASLC hot topic conference on liquid biopsy Oct 2-3! #LCSM |
| Laronica Conway @louisianagirl91 RT @BrendonStilesMD: We really appreciate everyone for joining the #lcsm community tonight. Always good to catch up and hear everyone's thoughts. Thanks for taking time from your busy schedules. Miss you all! |
| Brendon Stiles @BrendonStilesMD @aepriceny You are too young and energetic for old age to get you. Especially now with your modeling career taking off. Thanks for joining! #lcsm 🥰 |
| Brendon Stiles @BrendonStilesMD @sjwhitlock @lcsmchat Let's talk soon! #lcsm |
| Brendon Stiles @BrendonStilesMD RT @aepriceny: #lcsm @aepriceny celebrating 9month CT scan Cancer Free! Grateful and happy to be here! |
| Brendon Stiles @BrendonStilesMD Good night all! #lcsm |
 | brunolarvol.eth @brunolarvol RT @JackWestMD: |
 | May Cho @MayCho_MD Can’t wait for the future when we can define duration of IO smarter than what we currently do! |
| Bob Steele @steele_bob Good night folks. Look forward to seeing you at next month's Lung Cancer Social Media group chat. #lcsm |
| brunolarvol.eth @brunolarvol RT @JackWestMD: |
| Pashtoon Kasi MD, MS @pashtoonkasi RT @MayCho_MD: Can’t wait for the future when we can define duration of IO smarter than what we currently do! |
| brunolarvol.eth @brunolarvol RT @JackWestMD: |
| Bob Steele @steele_bob I have a video that will be shown at the conference - dealing with COVID-19. #LCSM |
 | Conservatives4PublicOption @PubOptConserv RT @OurWarOnCancer: #LungCancer is the #1cancerKiller (160,000/yr in US!) There is a painless screening test available 4 people at high risk. Fewer than 5% of those at high risk for LC get screened! An estimated 51% of #lungcancer deaths could be prevented if those people were screened! #LCSM https://t.co/JEnqBUzSzX |
| Janet Freeman-Daily @JFreemanDaily The transcript for tonight's #LCSM Chat "Crazy year, crazy progress–#lungcancer at #ESMO20" is here: https://t.co/hpvHTNXOHl |
 | Sewanti Limaye 🇮🇳🇺🇸 @SewantiLimaye RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽@ASCO #ctDNA🩸🧬 #CRCSM #PANCSM #LCSM #BCSM #oncology #Cancer @OncoAlert #CancerResearch #PrecisionMedicine #Research #Hope https://t.co/kjM5E9hrZR |
#LCSM content from Twitter.